Eileen Tanghal

In 2021, two women who had known each other for 30 years - since the days of MIT sorority life and electrical engineering problem sets in the mid-1990s - decided to stop being available to other people's funds and build their own. Eileen Tanghal and Dr. Tara Bishop founded Black Opal Ventures, a New York-based, women-led early-stage VC firm, with a specific thesis: that the collision of healthcare and frontier technology would produce the most important companies of the next decade.

That thesis didn't arrive by accident. Tanghal had spent the previous four years at In-Q-Tel - the nonprofit that invests in technology for the US Intelligence and Defense communities - where she led investments in AI, compute, and communications. Before that, she ran a $250M portfolio at Applied Ventures, the corporate venture arm of Applied Materials. Before that: ARM Holdings, Kennet Partners, Amadeus Capital in London, and her earliest days as one of the first engineers at a semiconductor startup called PDF Solutions, which IPO'd in 2002.

Two decades of investing. Five firms. Two continents. Forty-plus board seats. And then: her own fund, raised to $58M on the strength of that track record, backed by Eli Lilly, Bank of America, JPMorgan's Project Spark, Atlantic Health System, and a cohort of institutional investors who understand that when a former national-security investor decides healthcare is the frontier worth defending, it's worth paying attention.

Eileen Tanghal graduated from MIT in 1997 with a degree in Electrical Engineering and Computer Science and a minor in Economics - which, in hindsight, was exactly the combination venture capital requires. She joined PDF Solutions when it was still a startup, working on what we would now call digital twins for semiconductor manufacturing. The company's core insight - that you could model the physics of chip fabrication to catch defects before they became expensive - was ahead of its time. It went public in 2002.

She moved through the dot-com boom at AllAdvantage (the internet advertising startup that would not survive it), then made the jump that would define her career: she crossed the Atlantic to do an MBA at London Business School and emerged into European venture capital at Amadeus Capital Partners. That stint at Amadeus led to Kennet Partners, then back across to Silicon Valley and Applied Ventures.

At Applied Ventures - the strategic investment arm of Applied Materials, the world's largest semiconductor equipment company - Tanghal was a Managing Director running a $250M portfolio of nearly 50 companies across semiconductors, solar, display technology, and early life sciences. The range matters: it built her a technical intuition that spans materials science, systems engineering, and the kind of deep-tech infrastructure that other investors find too hard to underwrite.

From Applied Ventures, she moved to ARM Holdings as VP of New Business Ventures, then landed at In-Q-Tel in 2017. In-Q-Tel is not a normal VC firm. It's structured as a nonprofit strategic investor, finding commercial technology for the Central Intelligence Agency and broader US Intelligence Community. Tanghal led investments in AI, compute, and communications - companies like Cerebras, Mythic, EdgeQ, EdgeImpulse, and Twist Bioscience.

She also started talking to government officials. In 2019, she began advising US leaders on semiconductor policy. What she saw - a growing dependence on foreign chip manufacturing with serious national security implications - became the foundation for what eventually became the CHIPS and Science Act, signed by President Biden in August 2022. Her fingerprints are on that legislation.

Black opals are the rarest and most valuable of all opals. They don't look impressive until the light hits them at the right angle - then they ignite. It's a name that says something about what Tanghal and Bishop are looking for in companies and in founders.

Black Opal Ventures is an early-stage fund. Its thesis sits at the intersection of healthcare and what Tanghal calls "frontier technology" - AI and machine learning, computing at the edge, TinyML, digital twins, materials science, generative AI, robotics, bioengineering, and advanced computing. The portfolio reflects this: Ansa Biotechnologies (DNA synthesis), Conceivable Life Sciences (AI and microrobotics for IVF access), Empatica (seizure detection wristbands), Optellum (AI-assisted lung cancer diagnosis), Outpace Bio (next-gen cell therapy), Hyro (conversational AI for healthcare), FlyteHealth, and more.

The $58M debut fund closed in November 2023 with lead investors including Eli Lilly and Company, Bank of America, Atlantic Health System Venture Studio, JPMorgan Asset Management's Project Spark, New Summit Investments, Illumen Capital, Henry Ford Health, Women of the World Endowment, and Global Corporate Venturing. For a first-time fund, getting pharmaceutical companies, major banks, and health systems to commit is not a small thing.

The firm is also ImpactAssets 50-listed - a designation for fund managers with a credible track record in impact investing - and aligns with five UN Sustainable Development Goals. That's not marketing copy; the firm releases annual impact reports measuring portfolio performance against health equity metrics alongside financial returns.

The portfolio has 15+ companies across two funds. And nearly 70% of applicants for Black Opal positions in 2023 were women - a number that Tanghal points to with visible satisfaction, because she knows exactly why it's happening: when two women lead the firm, different people apply. The pipeline changes before you even start making decisions.

The portfolio spans AI-assisted diagnosis (Optellum's lung cancer platform), DNA synthesis infrastructure (Ansa Biotechnologies), IVF access via robotics and AI (Conceivable Life Sciences), next-generation cell therapy (Outpace Bio), and healthcare conversational AI (Hyro). What they share: they all sit at the intersection where a genuine scientific breakthrough meets a genuine healthcare problem. Tanghal's technical background means she can evaluate both sides of that equation.

Eileen Tanghal is not shy about what Black Opal Ventures is trying to do beyond generating returns. The firm is measuring impact on healthcare accessibility. It is deliberately recruiting underrepresented founders. It is counting the women and minority executives in its portfolio companies and reporting the numbers. This is not a separate track from the financial mission - she argues it's the same track.

That framing - profitable and inclusive, not profitable or inclusive - is characteristic of how Tanghal talks about the fund. The three-part definition of success she and Bishop use is careful and deliberate: financial returns for investors, impact on healthcare, and making venture capital more inclusive. All three. Not one, not two.

For Tanghal, this comes from a long career watching who gets funded and who doesn't, who gets the board seat and who doesn't, and what gets built as a result. The healthcare system's famous inequities - in access, in affordability, in outcomes across demographic lines - are not unrelated to who was in the room when the companies were being built. That's the underlying logic of the fund.

She and Bishop have been friends for three decades - they met as MIT undergraduates in the mid-1990s. They were in the same engineering courses. They did philanthropic work together. They were in the same sorority. Then they worked separately - Tanghal in venture capital and deep tech, Bishop in medicine and healthcare management at McKinsey and Weill Cornell and eventually as Chief Clinical Officer at Bind (acquired by UnitedHealth Group). Thirty years of knowing someone's values before you co-sign a fund with them is an unusual form of due diligence.

Her first company was PDF Solutions, a semiconductor startup whose core technology - modeling and digitally twinning semiconductor fabrication processes to catch defects before manufacture - was so early that "digital twins" wasn't yet a phrase anyone used. The company IPO'd in 2002. She was one of the first engineers there.

She's an IEEE member, which is not surprising for a semiconductor-trained MIT engineer, but it's also a signal of something: she never left the technical world even as she moved into finance. She can talk with founders about their technology at a level that most VCs can't reach.

At In-Q-Tel, she was writing checks to companies whose technology might one day be relevant to the CIA. That context shapes how you think about security infrastructure, about supply chains, about what "resilient" actually means. It also means her network includes people who think about national security alongside people who think about healthcare - an unusual combination.